Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

By P. Home, Stuart J. Pocock, H. Beck-Nielsen, R. Gomis, M. Hanefeld, N. Jones, M. Komajda, J. McMurray, Theodora S Temelkova-Kurktschiev. New England Journal of Medicine, 2007

804 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/22c8c809c4931e5ff834bfb0dfe8fe3b1d9d4fbd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Ralph B. D’Agostino
2. Bruce E. Kemp
3. G. Steinberg

In Molecular Biology

1. G. Steinberg
2. Bruce E. Kemp

Citations in the corpus

• AMPK in Health and Disease. (2009, background): “In light of recent studies demonstrating an increased incidence of myocardial ischemic events with rosiglitazone treatment (204, 417), it is interesting to speculate that this may be due to chronic 1058 GREGORY R.”
• Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review (2014, result): “However, some meta-analyses indicated that among patients with impaired glucose tolerance or type 2 diabetes the use of rosiglitazone for at least 12 months was associated with a significantly increased risk of myocardial infarction and heart failure, as well as with an elevated risk of cardiovascul”
• Canadian Diabetes Association Clinical Practice Guidelines Expert Committee (2013, neutral): “Although meta-analyses of smaller, underpowered studies suggested possible risk of MI with rosiglitazone (31,32), this has not been demonstrated in a larger randomized clinical trial (33,34).”
• Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. (2010, background): “For example, the discrepancy between diabetes trials targeting cardiovascular events and the low event rates in those trials illustrates the potential utility of the simple risk enrichment strategies found in the current analysis.(6) Planned trials of diabetic patients specifically designed to asses”
• Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus (2007, background): “31) for the primary end point of hospitalization or death from cardiovascular disease (29).”